Probiotics and methods for reducing appetite
By administering a combination of Akkermansia and Parabacterium bacteria, the difficulties in implementing the ketogenic diet were resolved, resulting in seizure protection, improved neurological function, reduced appetite, and applicability to the treatment and prevention of various neurological disorders.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- BLOOM TECHNOLOGY CO LTD
- Filing Date
- 2024-08-14
- Publication Date
- 2026-06-19
AI Technical Summary
The existing low-carbohydrate, high-fat ketogenic diet (KD) is difficult to implement in the treatment of epilepsy and other disorders, has poor dietary adherence and significant side effects, and the mechanism of its beneficial effects is unclear, resulting in low usage and difficulty in long-term adherence.
Subjects were given a combination of Akkermansia spp. (Akk) and Parabacterium spp. (Pb) bacteria, administered orally or rectally, in a ratio of 1:1, 3:1, 6:1, or 10:1, to mimic the effects of a ketogenic diet for the treatment or prevention of epilepsy and other neurological disorders.
It reduces appetite in subjects, mimics the effects of a ketogenic diet, provides protection against seizures, improves neurological function, reduces gamma-glutamyl transferase activity, increases the GABA/glutamate ratio, decreases gamma-glutamyl amino acids, and reduces seizures. It is suitable for the treatment and prevention of various neurological disorders.
Smart Images
Figure CN122249221A_ABST